Outcomes of patients with COVID-19 in the intensive care unit in Mexico: A multicenter observational study.

BACKGROUND: As of June 15, 2020, a cumulative total of 7,823,289 confirmed cases of COVID-19 have been reported across 216 countries and territories worldwide. However, there is little information on the clinical characteristics and outcomes of critically ill patients with severe COVID-19 who were admitted to intensive care units (ICUs) in Latin America. The present study evaluated the clinical characteristics and outcomes of critically ill patients with severe COVID-19 who were admitted to ICUs in Mexico. METHODS: This was a multicenter observational study that included 164 critically ill patients with laboratory-confirmed COVID-19 who were admitted to 10 ICUs in Mexico, from April 1 to April 30, 2020. Demographic data, comorbid conditions, clinical presentation, treatment, and outcomes were collected and analyzed. The date of final follow-up was June 4, 2020. RESULTS: A total of 164 patients with severe COVID-19 were included in this study. The mean age of patients was 57.3 years (SD 13.7), 114 (69.5%) were men, and 6.0% were healthcare workers. Comorbid conditions were common in patients with critical COVID-19: 38.4% of patients had hypertension and 32.3% had diabetes. Compared to survivors, nonsurvivors were older and more likely to have diabetes, hypertension or other conditions. Patients presented to the hospital a median of 7 days (IQR 4.5-9) after symptom onset. The most common presenting symptoms were shortness of breath, fever, dry cough, and myalgias. One hundred percent of patients received invasive mechanical ventilation for a median time of 11 days (IQR 6-14). A total of 139 of 164 patients (89.4%) received vasopressors, and 24 patients (14.6%) received renal replacement therapy during hospitalization. Eighty-five (51.8%) patients died at or before 30 days, with a median survival of 25 days. Age (OR, 1.05; 95% CI, 1.02-1.08; p<0.001) and C-reactive protein levels upon ICU admission (1.008; 95% CI, 1.003-1.012; p<0.001) were associated with a higher risk of in-hospital death. ICU length of stay was associated with reduced in-hospital mortality risk (OR, 0.89; 95% CI, 0.84-0.94; p<0.001). CONCLUSIONS: This observational study of critically ill patients with laboratory-confirmed COVID-19 who were admitted to the ICU in Mexico demonstrated that age and C-reactive protein level upon ICU admission were associated with in-hospital mortality, and the overall hospital mortality rate was high. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04336345.

Experience in the management of severe COVID-19 patients in an intensive care unit.

OBJECTIVE: To describe the clinical characteristics and management of severe COVID-19 patients. METHOD: Observational, descriptive, longitudinal, and retrospective study. RESULTS: 56 patients were admitted, of whom 80.3% (n = 45) were males with a mean age of 58 years [46-67]. The main comorbidities were obesity, high blood pressure, and diabetes. Symptoms onset time at admittance to the ICU was 9 [7-14] days, of which the most frequent were dyspnea, fever, and dry cough. Laboratory data were lymphopenia; elevation of LDH, fibrinogen, D-dimer, ferritin and CRP. 100% of the patients required mechanical ventilation, the median mechanical ventilation time was 12 [6-17] days, and 66% (n= 37) required a prone position. The pharmacological treatment was mainly based on azithromycin, hydroxychloroquine, tocilizumab and steroids. The most frequent complications were acute kidney injury, venous thromboembolism and acute myocardial infarction. Mortality rate was 17.8% (n = 10). CONCLUSION: The characteristics of the critically ill patients in our hospital were mostly elderly and obese, with the variables of higher SOFA score and acute kidney injury associated with higher mortality.

OBJETIVO: Describir las características clínicas y el manejo de pacientes graves con COVID-19. MÉTODO: Estudio observacional, descriptivo, longitudinal y restrospectivo. RESULTADOS: Ingresaron 56 pacientes, el 80.3% (n = 45) de sexo masculino, con un promedio de edad de 58 [46-67] años. Las principales condiciones de comorbilidad fueron obesidad, hipertensión y diabetes. El tiempo de inicio de los síntomas al ingreso fue de 9 [7-14] días, siendo los más frecuentes disnea, fiebre y tos seca. Los datos de laboratorio fueron linfopenia y elevación de deshidrogenasa láctica, fibrinógeno, dímero D, ferritina y proteína C reactiva. El 100% de los pacientes requirieron ventilación mecánica, con una mediana de tiempo de ventilación de 12 [6-17] días, y el 66% (n = 37) requirieron posición en prono. El tratamiento farmacólogico fue a base de azitromicina, hidroxicloroquina, tocilizumab y esteroides, principalmente. Las complicaciones más frecuentes fueron lesión renal aguda, enfermedad tromboembólica venosa e infarto agudo al miocardio. La tasa de mortalidad fue del 17.8% (n = 10). CONCLUSIÓN: Los pacientes graves en nuestro hospital fueron en su mayoría personas de la tercera edad y con obesidad, siendo las variables de mayor puntaje SOFA y lesión renal aguda las asociadas con mayor mortalidad.

[Correlación de variables ecocardiográficas y biomarcadores en pacientes graves con COVID-19].

Objetivo: Describir las variables ecocardiográficas de los pacientes con COVID-19 y su correlación con biomarcadores y mortalidad. Método: Estudio observacional, descriptivo, longitudinal y retrospectivo. Resultados: El 70% (n = 21) eran de sexo masculino, el promedio de edad fue de 59 (46-67) años y el índice de masa corporal fue de 30.1 (27.3-32.4) kg/m2. En la evaluación de la función sistólica del ventrículo izquierdo se observó una adecuada correlación entre la excursión sistólica del plano del anillo mitral (MAPSE) y la fracción de eyección del ventrículo izquierdo (r2 = 0.508, p = 0.004). La evaluación de la función sistólica del ventrículo derecho indicó una óptima correlación entre la excursión sistólica del plano del anillo tricuspídeo (TAPSE) y la fracción de acortamiento del ventrículo derecho (r2 = 0.649, p = ≤ 0.0001). No hubo correlación de los biomarcadores y las variables ecocardiográficas entre los pacientes sobrevivientes y no sobrevivientes, a excepción del MAPSE y las concentraciones séricas de deshidrogenasa láctica (r2 = -0.427, p = 0.019). La tasa de mortalidad fue del 16% (n = 5). Conclusión: Existe una adecuada correlación entre las variables ecocardiográficas de la función sistólica del ventrículo izquierdo y del ventrículo derecho, así como también entre la MAPSE y los valores séricos de DHL.